Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM

Tohoku Journal of Experimental Medicine

Volumn 183, Issue 3, 1997, Pages 173-183

  Yamasaki, Yoshimitsu ^a   Kawamori, Ryuzo ^b   Wasada, Taro ^c   Sato, Akiko ^c   Omori, Yasue ^c   Eguchi, Hideyuki ^d   Tominaga, Makoto ^d   Sasaki, Hideo ^e   Ikeda, Masahiko ^a   Kubota, Minoru ^a   Ishida, Yoshihiko ^e   Hozumi, Toshiki ^e   Baba, Shigeaki ^e   Uehara, Masaya ^f   Shichiri, Motoaki ^f   Kaneko, Toshio ^g  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

^e HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^f KUMAMOTO UNIVERSITY   (Japan)

^g YAMAGUCHI ROSAI HOSPITAL   (Japan)

Author keywords

Glucose clamp; Insulin resistance; Lipid; Pioglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; CHOLESTEROL; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0001782187     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.183.173     Document Type: Article

References (21)

1. Akanuma, Y., Kosaka, K., Kuzuya, T., Shigeta, Y. & Kaneko, T. (1993) Long-term study of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus. J. Clin. Therap. Med., 9, Supl., 127-149. (in Japanese)
2. Arner, P., Pollare, T. & Lithell, H. (1991) Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia, 34, 482-487.
3. De Fronzo, R.A., Tobin, J.D. & Andre, R. (1979) Glucose-clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol., 237, E214-E233.
4. Efendic, S. & O'stenson, C.G. (1993) Hormonal responses and future treatment of non-insulin-dependent diabetes mellitus (NIDDM). J. Intern. Med., 234, 127-138.
5. Erikson, J., Frassilia-Kallunki, A., Ekstrand, A., Saloranta, C., Widen, E., Schalin, C. & Group, L. (1989) Early metabolic defects in person at increased risk for non-insulin-dependent diabetes mellitus. N. Engl. J. Med., 321, 337-343.
6. Firth, R.G., Bell, P.M. & Rizza, R.A. (1986) Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med., 314, 1280-86.
7. 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell, 83, 803-812.
8. Garvey, W.T., Olefsky, J.M., Griffin, J., Hamman, R.F. & Kolterman, O.G. (1985) The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes, 34, 222-234.
9. Hayakawa, T., Shiraki, T., Morimoto, T., Shii, K. & Ikeda, H. (1996) Pioglitazone improves insulin signaling defects in skeletal muscle from wistar fatty (fa/fa) rats. Biochem. Biophysi. Res. Commun., 223, 439-444.
10. Hofmann, A., Lorenz, K. & Colca, J.R. (1991) Glucose transport deficiency in diabetic animals in corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology, 129, 915-1925.
11. Kawamori, R., Bando, K., Yamasaki, Y., Kubota, M., Wasada, T., Iwama, N., Shichiri, M. & Kamada, T. (1989) Fasting plus prandial insulin supplements improve insulin secretary ability in non-insulin dependent diabetics. Diabetes Care, 12, 680-685.
12. Kemnitz, J.W., Elson, D.F., Roecker, E.B., Baum, S.T., Bergman, R.N. & Maglasson, M.D. (1994) Pioglitazone increase insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes, 43, 204-211.
13. Lehmann, J., Moore, L.B., Smith-Oliver, T.A., Wilkinson, W.O., Willson, T.M. & Kliewer, S.A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem., 270, 12953-12956.
14. Mimura, K., Umeda, F., Hiramatsu, S., Tanaiguchi, S., Ono, Y., Nakashima, N., Kobayashi, K., Masakado, M., Sako, Y. & Nawata, H. (1994) Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med., 11, 685-691.
15. Revers, R.R., Fink, R., Griffin, J., Olefsky, J.M. & Kolterman, O.G. (1989) Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J. Clin. Invest, 73, 664-672.
16. Sekiya, M., Yamasaki, Y., Tsujino, T., Shiba, Y., Kubota, M., Kawamori, R. & Kamada, T. (1995) Insulin resistance in essential hypertensive patients with impaired glucose tolerance. Diabetes Res. Clin. Pract., 29, 49-56.
17. Shichiri, M., Kawamori, R. & Yamasaki, Y. (1991) Clinical applications of a bedside-type artificial endocrine pancreas -Development and application of the control algorithm. Artif. Organs Today, 1, 13-22.
18. Sugiyama, Y., Shimura, Y. & Ikeda, H. (1990a) Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzeim-Forsh/Drug Res., 40, 436-440.
19. Sugiyama, Y., Taketomi, S., Shimura, Y., Ikeda, H. & Fujita, T. (1990b) Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzeim-Forth/ Drag Res., 40, 263-267.
20. Suter, S.L., Nlan, J.J., Wallace, P., Gumbiner, B. & Olfsky, J.M. (1992) Metabolic effects of a new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care, 15, 193-203.
21. World Health Organization (1985) Diabetes mellitus: A report of WHO Study Group. Technical Report Series No. 727, World Health Organigation, Geneva.